Prioritisation activity in the June quarter

Pharmac’s Prioritisation Update provides the latest information about applications for medicines, vaccines, and related products that we’ve assessed for funding. Proactively releasing this information is part of our ongoing commitment to transparency.

Every year we receive over 100 funding applications from health care professionals, consumer groups and suppliers. These applications include requests to fund new medicines and to widen access to medicines that we already fund.

We ask our clinical advisory committees to assess the available evidence and recommend whether we should fund, defer, or decline the applications. With their advice, we work to complete an assessment, including a health economic appraisal if required.

We apply the Factors for Consideration throughout our assessment of an application. The factors consider four areas: health need, health benefit, suitability, and costs and savings.

Once the assessment is complete, we take the application to a quarterly internal prioritisation meeting and add applications to one of the following priority lists:

We rank applications on our options for investment (OFI) list from highest to lowest priority but keep these rankings confidential so that we can negotiate the best prices with suppliers.

As of 30 June 2026, there are 162 applications on the OFI.

During the June prioritisation quarter, we ranked 18 new proposals on the OFI list.